The cohort that received genetic testing beyond the current standards (such as determination of KRAS status in left-sided colorectal cancer) was heavily biased towards cholangiocellular carcinomas (48.3%), followed by colon carcinomas (16.9%), pancreatic carcinomas (14.4%) and gastric carcinomas (7.6%) (Fig. 1a). The gene discussed is KRAS; the disease is exocrine pancreatic carcinoma.